Association of phenylbutazone usage with horses bought for slaughter: A public health risk

Food and Chemical Toxicology

Volumn 48, Issue 5, 2010, Pages 1270-1274

  Dodman, Nicholas ^a   Blondeau, Nicolas ^b   Marini, Ann M ^c  

^a TUFTS UNIVERSITY   (United States)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Agranulocytosis; Aplastic anemia; Food safety; Phenylbutazone; Racehorse; Residue; Thoroughbred

Indexed keywords

PHENYLBUTAZONE;

ARTICLE; DRUG USE; FOOD INTAKE; HEALTH HAZARD; HORSE; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; PUBLIC HEALTH; SLAUGHTERHOUSE; UNITED STATES;

ABATTOIRS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONSUMER PRODUCT SAFETY; DRUG RESIDUES; FOOD CONTAMINATION; HORSES; HUMANS; MEAT; PHENYLBUTAZONE; RISK ASSESSMENT; UNITED STATES; UNITED STATES DEPARTMENT OF AGRICULTURE; UNITED STATES FOOD AND DRUG ADMINISTRATION;

ANIMALIA; EQUIDAE;

EID: 77951608348     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.02.021     Document Type: Article

References (23)

1. Benjamin S.B., Ishak K.G., Zimmerman H.J., Grushka A. Phenylbutazone liver injury: a clinical-pathologic survey of 23 cases and review of the literature. Hepatology 1981, 1:255-263.
2. Böttiger L.E., Westerhom B. Drug-induced blood dyscrasias. Br. Med. J. 1973, 2:339-343.
3. Cameron A., Eisen A.A., Niranjan L.M. Aplastic anaemia due to phenylbutazone. Postgrad. Med. J. 1966, 42:49-51.
4. Chaplin S. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone and chloramphenicol. Part I. Adv. Drug React. Acute Poisoning Rev. 1986, 12:97-136.
5. Empacadora de Carnes de Fresnillo vs Tim Curry, Tarrant Country Texas, 2007.
6. Deaths due to butazolidin, 1952. Br. Med. J. 2, 1427.
7. Dunn P.S. A clinician's view on the use and misuses of phenylbutazone. Equine Vet. J. 1972, 4:63-65.
8. Etess A.D., Jacobson A.S. Fatality due to agranulocytosis following use of phenylbutazone (butazolidin). JAMA 1953, 151:639-640.
9. Goodrich L.R., Nixon A.J. Medical treatment of osteoarthritis in the horse - a review. Vet. J. 2006, 7:51-69.
10. Hale G.S., DeGruchy G.C. Aplastic anaemia following the administration of phenylbutazone. Med. J. Aust. 1960, 47:449-453.
11. Hopes R. Use and misuses of anti-inflammatory drugs in race horses. Equine Vet. J. 1972, 4:66-70.
12. Lees P., Maitho T.E., Taylor J.B. Pharmacokinetics of phenylbutazone in two age groups of ponies. Vet. Rec. 1985, 116:229-232.
13. Lees P., Taylor J.B.O., Higgins A.J., Sharma S.C. Phenylbutazone and oxyphenbutazone distribution into tissue fluids in the horse. J. Vet. Pharmacol. Ther. 1986, 9:204-212.
14. Lees P., Taylor J.B., Maitho T.E., Millar J.D., Higgins A.J. Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. Cornell Vet. 1987, 77:192-211.
15. Leonard J.C. Toxic effects of phenylbutazone with special reference to disorders of blood. Br. Med. J. 1953, 1:1311-1313.
16. Maitho T.E., Lees P., Taylor J.B. Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. J. Vet. Pharmacol. Ther. 1986, 9:26-39.
17. Mauer E.F. The toxic effects of phenylbutazone (butazolidin); review of the literature and report of the twenty-third death following its use. N. Engl. J. Med. 1955, 253:404-410.
18. McCombs A.P. Case histories of two patients with toxic symptoms of drug reaction. J. Am. Women's Assoc. 1958, 13:263-267.
19. McConnico R.S., Morgan T.W., Williams C.C., Hubert J.D., Moore R.M. Pathophysiologic effects of phenylbutazone on the right dorsal colon in horses. Am. J. Vet. Res. 2008, 69:1496-1505.
20. Nelson L., Shih R., Hoffman R. Aplastic anemia induced by an adulterated herbal medication. J. Toxicol. Clin. Toxicol. 1995, 33:467-470.
21. Ramsey R., Golde D.W. Aplastic anemia from veterinary phenylbutazone. JAMA 1976, 236:1049.
22. Risks of agranulocytosis and aplastic anemia, 1986. A first report of their relation to drug use with special reference to analgesics. The international agranulocytosis and aplastic anemia study. JAMA 256, 1749-1757.
23. Steinberg C.L., Bohrod M.G., Roodenberg A.I. Agranulocytosis following phenylbutazone (butazolidin) therapy; report of a fatal case. JAMA 1953, 152:33-36.